ArticleVaccine2008
Lactococcus lactis-expressing listeriolysin O (LLO) provides protection and specific CD8(+) T cells against Listeria monocytogenes in the murine infection model.
Article in Vaccine, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 55 citations in OpenAlex.
- Review
- Subcellular Localization Dictates Therapeutic Function: Spatially Targeted Delivery of Amuc_1100 by EngineeredNutrients · 2025Article
- Lactococcus lactis, a bacterium with probiotic functions and pathogenicity.World journal of microbiology & biotechnology · 2023Review
- Lactococcus lactis expressing sand fly PpSP15 salivary protein confers long-term protection against Leishmania major in BALB/c mice.PLoS neglected tropical diseases · 2020Article
- Article
- Listeria monocytogenes mutants defective in gallbladder replication represent safety-enhanced vaccine delivery platforms.Human vaccines & immunotherapeutics · 2016Article
- Subtilisin QK-2: secretory expression in Lactococcus lactis and surface display onto gram-positive enhancer matrix (GEM) particles.Microbial cell factories · 2016Article
- Fusion protein comprised of the two schistosomal antigens, Sm14 and Sm29, provides significant protection against Schistosoma mansoni in murine infection model.BMC infectious diseases · 2015Article
- Recombinant Lactobacillus plantarum induces immune responses to cancer testis antigen NY-ESO-1 and maturation of dendritic cells.Human vaccines & immunotherapeutics · 2015Article
- Two-tiered biological containment strategy for Lactococcus lactis-based vaccine or immunotherapy vectors.Human vaccines & immunotherapeutics · 2014Article
- Development of vaccine delivery vehicles based on lactic acid bacteria.Molecular biotechnology · 2012Review
- Article
- Lactococci and lactobacilli as mucosal delivery vectors for therapeutic proteins and DNA vaccines.Microbial cell factories · 2011Review
- Evaluation of oral immunization with recombinant avian influenza virus HA1 displayed on the Lactococcus lactis surface and combined with the mucosal adjuvant cholera toxin subunit B.Clinical and vaccine immunology : CVI · 2011Article
- Immune responses elicited in mice with recombinant Lactococcus lactis expressing F4 fimbrial adhesin FaeG by oral immunization.Veterinary research communications · 2010Article
- Genome organization and characterization of the virulent lactococcal phage 1358 and its similarities to Listeria phages.Applied and environmental microbiology · 2010Article
- Oral vaccination of mice against Helicobacter pylori with recombinant Lactococcus lactis expressing urease subunit B.FEMS immunology and medical microbiology · 2009Article
- A new plasmid vector for DNA delivery using lactococci.Genetic vaccines and therapy · 2009Article
- Efficacy of a Lactococcus lactis ΔpyrG vaccine delivery platform expressing chromosomally integrated hly from Listeria monocytogenes.Bioengineered bugsArticle
- Development of a novel oral vaccine against Mycobacterium avium paratuberculosis and Johne disease: a patho-biotechnological approach.Bioengineered bugsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lactococcus lactis has previously been proposed as a vaccine platform for the safe delivery of heterologous antigens. Here we utilized L. lactis as a live vector for expression of listeriolysin O (LLO), a major Listeria monocytogenes antigen and virulence factor. A variety of plasmid constructs were designed to permit either constitutive or nisin-inducible expression of secreted or non-secreted LLO in L. lactis. Recombinant strains were subsequently tested in a murine model for vaccination efficacy against L. monocytogenes infection. CD8(+) T lymphocytes specific for the LLO(91-99) epitope were detected when strains were administered via the intraperitoneal (IP) but not the oral route. Challenge with live L. monocytogenes revealed different levels of protection among the three vaccine strains tested with the nisin-inducible LLO-secreting L. lactis strain providing the greatest protection against secondary infection. This work highlights the usefulness of the GRAS (Generally Regarded As Safe) organism L. lactis as the basis of a live vaccine vector against L. monocytogenes. The work suggests that LLO-expressing L. lactis strains may also have the potential to act as a platform for directing other co-expressed antigens towards the cytosolic MHC class I pathway for enhanced stimulation of the CD8(+) T-cell response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.